期刊
MULTIPLE SCLEROSIS JOURNAL
卷 13, 期 9, 页码 1118-1126出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458507078916
关键词
autoimmune; chelation; deferiprone; desferrioxamine; experimental allergic encephalomyelitis; iron; T cells
资金
- NIA NIH HHS [AG23946] Funding Source: Medline
- NICHD NIH HHS [HD 02528] Funding Source: Medline
The iron chelator, Desferal, suppressed disease activity of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), and it has been tested in pilot trials for MS. The administration regimen of Desferal is cumbersome and prone to complications. Orally-deliverable, iron chelators have been developed that circumvent these difficulties, and the objective of this study was to test an oral chelator in EAE. SJL mice with active EAE were randomly assigned to receive deferiprone (150 mg/kg) or vehicle (water) 2 x/day via gavage. EAE mice given deferiprone had significantly less disease activity and lower levels of inflammatory cell infiltrates (revealed by H&E staining) than EAE mice administered vehicle. T-cell infiltration, assessed by anti-CD3 immunohistochernical staining, also was reduced, although not significantly. Splenocytes cultured from naive SJL mice were stimulated with anti-CD3 and anti-CD28 with or without 250 mu M deferiprone. While similar to 39% of costimulated splenocytes without deferiprone underwent division, only similar to 2.8% of costimulated splenocytes with deferiprone divided and the latter cells were only 53% as viable as the former. Deferiprone had no effect on proliferation or viability of cells that were not costimulated. In summary, deferiprone effectively suppressed active EAE disease and it inhibited T-cell function.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据